KDM2A and Alzheimer disease: A study focusing on JmjC KDMs in tauopathies reports expression levels of FBXL11 (KDM2A), JMJD1A/B (KDM3A/B), and JMJD2A/B (KDM4A/B) are substantially higher in post mortem prefrontal cortex tissue from patients with AD compared to controls, whereas FBXL10 (KDM2B) mRNA levels are downregulated in the AD patient brain.115